Clinically Probable Generalized Bullous Pemphigoid in an 81-Year-Old Woman: A Case Report
DOI:
https://doi.org/10.55606/detector.v4i2.6643Keywords:
Autoimmune Blistering Disease, Bullous Pemphigoid, Direct Immunofluorescence, Older Adult, Resource-Limited SettingAbstract
Bullous pemphigoid is the most common autoimmune subepidermal blistering disorder in older adults, but definitive diagnosis generally requires immunopathologic confirmation. This report describes an 81-year-old Indonesian woman with a one-week history of generalized, symmetric, tense bullae measuring approximately 0.5-3 cm on erythematous skin, accompanied by erosions, crusting, and several purulent-appearing lesions. Oral and genital mucosae were unaffected. Histopathology, direct and indirect immunofluorescence, BP180/BP230 serology, and bacterial culture were unavailable. Based on advanced age, generalized tense bullae, absent mucosal involvement, and lack of scarring, clinically probable generalized bullous pemphigoid with suspected secondary bacterial infection was diagnosed. Treatment included systemic methylprednisolone, topical clobetasol, wound care, antihistamine therapy, and empiric antibiotics. During six days of hospitalization, new blister formation appeared to decrease and many lesions became dry and crusted, although long-term follow-up was unavailable. The case emphasizes that diagnostic certainty must match the available evidence. In resource-limited settings, referral for immunopathologic confirmation, toxicity-conscious corticosteroid use, microbiologically guided antibiotic therapy, and close monitoring of older patients remain essential.
Downloads
References
Borradori, L., Van Beek, N., Feliciani, C., Tedbirt, B., Antiga, E., Bergman, R., et al. (2022). Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 36(10), 1689-1704. https://doi.org/10.1111/jdv.18220
Cao, P., Xu, W., & Zhang, L. (2022). Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: A systematic review. Frontiers in Immunology, 13, 928621. https://doi.org/10.3389/fimmu.2022.928621
Chen, Y., Sun, K., & Chang, J. (2026). Dupilumab treatment outcomes in bullous pemphigoid: A systematic review and single-arm meta-analysis. Frontiers in Immunology, 17, 1651543. https://doi.org/10.3389/fimmu.2026.1651543
Gagnier, J. J., Kienle, G., Altman, D. G., Moher, D., Sox, H., Riley, D., & CARE Group. (2014). The CARE guidelines: Consensus-based clinical case reporting guideline development. Journal of Clinical Epidemiology, 67(1), 46-51. https://doi.org/10.1016/j.jclinepi.2013.08.003
Huang, D., Zhang, Y., Yu, Y., Jiang, Y., Kong, L., Ding, Y., et al. (2023). Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study. International Immunopharmacology, 125(Pt A), 111157. https://doi.org/10.1016/j.intimp.2023.111157
Joly, P., Roujeau, J. C., Benichou, J., Picard, C., Dreno, B., Delaporte, E., et al. (2002). A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. The New England Journal of Medicine, 346(5), 321-327. https://doi.org/10.1056/NEJMoa011592
Karakioulaki, M., Eyerich, K., & Patsatsi, A. (2024). Advancements in bullous pemphigoid treatment: A comprehensive pipeline update. American Journal of Clinical Dermatology, 25(2), 195-212. https://doi.org/10.1007/s40257-023-00832-1
Kridin, K., & Ludwig, R. J. (2018). The growing incidence of bullous pemphigoid: Overview and potential explanations. Frontiers in Medicine, 5, 220. https://doi.org/10.3389/fmed.2018.00220
Kridin, K., Schwartz, N., Cohen, A. D., & Zelber-Sagi, S. (2018). Mortality in bullous pemphigoid: A systematic review and meta-analysis of standardized mortality ratios. The Journal of Dermatology, 45(9), 1094-1100. https://doi.org/10.1111/1346-8138.14503
Lai, Y. C., Yew, Y. W., & Lambert, W. C. (2016). Bullous pemphigoid and its association with neurological diseases: A systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology, 30(12), 2007-2015. https://doi.org/10.1111/jdv.13660
Langan, S. M., Smeeth, L., Hubbard, R., Fleming, K. M., Smith, C. J. P., & West, J. (2008). Bullous pemphigoid and pemphigus vulgaris: Incidence and mortality in the UK: Population-based cohort study. BMJ, 337, a180. https://doi.org/10.1136/bmj.a180
Meijer, J. M., Diercks, G. F. H., de Lang, E. W. G., Pas, H. H., & Jonkman, M. F. (2019). Assessment of diagnostic strategy for early recognition of bullous and nonbullous variants of pemphigoid. JAMA Dermatology, 155(2), 158-165. https://doi.org/10.1001/jamadermatol.2018.4390
Oren-Shabtai, M., Mimouni, D., Nosrati, A., Atzmony, L., Kaplan, B., Barzilai, A., & Baum, S. (2023). Biological treatment for bullous pemphigoid. Frontiers in Immunology, 14, 1157250. https://doi.org/10.3389/fimmu.2023.1157250
Persson, M. S. M., Harman, K. E., Thomas, K. S., Chalmers, J. R., Vinogradova, Y., Langan, S. M., et al. (2021). Long-term oral prednisolone exposure in primary care for bullous pemphigoid: Population-based study. British Journal of General Practice, 71(713), e904-e911. https://doi.org/10.3399/BJGP.2020.0870
Persson, M. S. M., Begum, N., Grainge, M. J., Harman, K. E., Grindlay, D., & Gran, S. (2022). The global incidence of bullous pemphigoid: A systematic review and meta-analysis. British Journal of Dermatology, 186(3), 414-425. https://doi.org/10.1111/bjd.20743
Powers, C. M., Thakker, S., Gulati, N., Talia, J., Dubin, D., Zone, J., et al. (2025). Bullous pemphigoid: A practical approach to diagnosis and management in the modern era. Journal of the American Academy of Dermatology, 92(6), 1337-1350. https://doi.org/10.1016/j.jaad.2025.01.086
Sárdy, M., Kostaki, D., Varga, R., Peris, K., & Ruzicka, T. (2013). Comparative study of direct and indirect immunofluorescence and of BP180 and BP230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. Journal of the American Academy of Dermatology, 69(5), 748-753. https://doi.org/10.1016/j.jaad.2013.07.009
Schmidt, E., & Zillikens, D. (2013). Pemphigoid diseases. The Lancet, 381(9863), 320-332. https://doi.org/10.1016/S0140-6736(12)61140-4
Singh, S., Kirtschig, G., Anchan, V. N., Chi, C. C., Taghipour, K., Boyle, R. J., & Murrell, D. F. (2023). Interventions for bullous pemphigoid. Cochrane Database of Systematic Reviews, 8, CD002292. https://doi.org/10.1002/14651858.CD002292.pub4
Vaillant, L., Bernard, P., Joly, P., Prost, C., Labeille, B., Bedane, C., et al. (1998). Evaluation of clinical criteria for diagnosis of bullous pemphigoid. Archives of Dermatology, 134(9), 1075-1080. https://doi.org/10.1001/archderm.134.9.1075
Werth, V. P., Murrell, D. F., Joly, P., Heck, R., Orengo, J. M., Ardeleanu, M., & Hultsch, V. (2024). Pathophysiology of bullous pemphigoid: Role of type 2 inflammation and emerging treatment strategies (narrative review). Advances in Therapy, 41(12), 4418-4432. https://doi.org/10.1007/s12325-024-02992-w
Williams, H. C., Wojnarowska, F., Kirtschig, G., Mason, J., Godec, T. R., Schmidt, E., et al. (2017). Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: A pragmatic, non-inferiority, randomised controlled trial. The Lancet, 389(10079), 1630-1638. https://doi.org/10.1016/S0140-6736(17)30560-3
Zhao, L., Wang, Q., Liang, G., Zhou, S., Li, J., Zhang, J., et al. (2023). Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatology, 159(9), 953-960. https://doi.org/10.1001/jamadermatol.2023.2428
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Refa Rahmaddiansyah, Ahmad Lutfi, Sukarsi Rusti, Azizah AR

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.





